Inhibition of Early Mouse Plasmacytoma Development in Case of Plasmodium Infection
Asian Journal of Immunology, Volume 6, Issue 1,
Page 69-75
Abstract
Background: Inhibition of early cancer development, through enhancement of cancer immunosurveillance by innate cells has been reported after infection with different microorganisms. Since Plasmodium infection modulates the innate immune system, we examined the effect of Plasmodium infection on cancer immunosurveillance.
Methods: As a model, we used Plasmodium yoelii 265 BY infection of BALB/c mice and administration of TEPC.1033.C2 plasmacytoma cells.
Results: Plasmodium infection effectively inhibited the early development of plasmacytoma. The protective effect of infection was not due to a direct cytopathic destruction of cancer cells by the parasite. Plasmodium infection induced the production of proinflammatory cytokines such as interleukin-12 and interferon-gamma, known to be involved in cancer immunosurveillance. Depletion of ASGM1+ cells in vivo largely suppressed the protective effect of the parasite.
Conclusions: Plasmodium infection could influence on the inhibition of early mouse plasmacytoma. This observation suggest Plasmodium infections in humans might participate to the low incidence of multiple myeloma in countries where malaria is frequent and should be taken into account in public health policy of these countries.
- Plasmodium yoelii
- plasmacytoma
- interferon-gamma
- interleukin-12
- ASGM1 cells
How to Cite
References
Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006;6:836–848. Available:https://doi.org/10.1038/nri1961
Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH. Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr. Opin. Immunol. 2016;38:52-58. Available:https://doi.org/10.1016/j.coi.2015.11.001.
Albonico HU, Bräker HU, Hüsler J, Febrile infectious childhood diseases in the history of cancer patients and matched controls. Med. Hypotheses. 1998;51:315–320. Available:https://doi.org/10.1016/S0306-9877(98)90055-X.
Oikonomopoulou K, Brinc D, Kyriacou K, Diamandis EP. Infection and cancer: Revaluation of the hygiene hypothesis. Clin. Cancer Res. 2013;19:2834-2841. Available:https://doi.org/10.1158/1078-0432.CCR-12-3661
Thirion G, Saxena A, Hulhoven X, Markine-Goriaynoff D, Van Snick J, Coutelier JP. Modulation of the host microenvironment by a common non-oncolytic mouse virus leads to inhibition of plasmacytoma development through NK cell activation. J. Gen. Virol. 2014;95:504-509. Available:https://doi.org/10.1099/vir.0.063990-0
De Beule N, Menu E, Bertrand MJM, Favreau M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez S, Vanderkerken K, De Trez C. Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells. Oncotarget. 2017;8:52016-25.
Available:https://doi.org/10.18632/oncotarget.18152.
Mandour M, Soe PP, Uyttenhove C, Van Snick J, Marbaix E, Coutelier JP. Lactate dehydrogenase-elevating virus enhances natural killer cell-mediated immunosurveillance of mouse mesothelioma development. Infect. Agent. Cancer. 2020;15:30. Available:https://doi.org/10.1186/s13027-020-00288-6
Mandour MF, Soe PP, Castonguay AS, Van Snick J, Coutelier JP. Inhibition of IL-12 heterodimers impairs TLR9-mediated prevention of early mouse plasmacytoma cell growth. Front. Med. 2022;9:1057252.
Available:https://doi.org/10.3389/fmed.2022.1057252.
Georgakopoulou R, Fiste O, Sergentanis TN, Andrikopoulou A, Zagouri F, Gavriatopoulou M, Psaltopoulou T, Kastritis E, Terpos E, Dimopoulos MA. Occupational exposure and multiple myeloma risk: An updated review of meta-analyses. J Clin Med. 2021;10:4179. Available:https://doi.org/10.3390/jcm10184179
Becker N. Epidemiology of multiple myeloma, In: Moehler T, Goldschmidt H (Eds), Multiple myeloma. Recent Results in Cancer Research, Springer, Berlin, Heidelberg. 2011;183:25-35.
Roetinck S, Baratin M. Johansson S. Lemmers C. Vivier E. Ugolini S. Natural killer cells and malaria. Immunol. Rev. 2006;214:251-263. Available:https://doi.org/10.1111/j.1600-065X.2006.00446.x
Uyttenhove C, Arendse B, Stroobant V, Brombacher F, Van Snick J. Development of an anti-IL-12 p40 auto-vaccine: Protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. 2004;34:3572-3581. Available:https://doi.org/10.1002/eji.200425443.
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob. Health. 2020;8:180–190.
Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, Chen L, Zhong N, Chen X, Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. Plos One. 2011;6:e24407.
Available:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024407.
Pan J, Ma M, Qin L, Kang Z, Adah D, Tao Z, Li X, Dai L, Zhao S, Chen X, Zhou Q. Plasmodium infection inhibits triple negative 4T1 breast cancer potentially through induction of CD8+ T cell-mediated antitumor responses in mice. Biomed. Pharmacother. 2021;138:111406.
Available:https://doi.org/10.1016/j.biopha.2021.111406.
Liang Y, Chen X, Tao Z, Ma M, Adah D, Li X, Dai L, Ding W, Fanuel S, Zhao S, Qin L, Chen X, Zhang X. Plasmodium infection prevents recurrence and metastasis of hepatocellular carcinoma possibly via inhibition of the epithelial‑mesenchymal transition. Mol. Med. Rep. 2021;23:418. Available:https://doi.org/10.3892/mmr.2021.12057
Wang B, Li Q, Wang J, Zhao S, Nashun B, Qin L, Chen X. Plasmodium infection inhibits tumor angiogenesis through effects on tumor-associated macrophages in a murine implanted hepatoma model. Cell Commun. Signal. 2020;18:157. Available:https://doi.org/10.1186/s12964-020-00570-5
Chen X, Qin L, Hu W, Adah D. The mechanisms of action of Plasmodium infection against cancer. Cell Commun. Signal. 2021;19:74. DOI: 10.1186/s12964-021-00748-5
Yao X, Cao Y, Lu L, Xu Y, Chen H, Liu C, Chen D, Wang K, Xu J, Fang R, Xia H, Li J, Fang Q, Tao Z. Plasmodium infection suppresses colon cancer growth by inhibiting proliferation and promoting apoptosis associated with disrupting mitochondrial biogenesis and mitophagy in mice. Parasit. Vectors. 2022;15:192. DOI: 10.1186/s13071-022-05291-x
Kosaka A, Wakita D, Matsubara N, Togashi Y, Nishimura SI, Kitamura H, Nishimura T. AsialoGM1+CD8+ central memory-type T cells in unimmunized mice as novel immunomodulatory of IFN--dependent type 1 immunity. Intern. Immunol. 2007;19:249-256. Available:https://doi.org/10.1093/intimm/dxl140
Javaid N, Choi S. Toll-like receptors from the perspective of cancer treatment. Cancers. 2020;12(2):297. DOI: 10.3390/cancers12020297
Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O, Itagaki S, et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. 2005;201:19-25.
Available:https://doi.org/10.1084/jem.20041836.
Tugues S, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22:237-246.
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B. The TNF paradox in cancer progression and immunotherapy. Front. Immunol. 2019;10: 1818. Available:https://doi.org/10.3389/fimmu.2019.01818
-
Abstract View: 2 times
PDF Download: 1 times
